Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

How do you explain one Zantac manufacturer kiboshing a favorable trend of defense verdicts and decisions – with a massive $2.2 billion settlement? The answer appears to lie with the whistleblower suit ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

Although the Zantac settlement resolution announced earlier this month significantly reduced GSK’s litigation uncertainty, the recent meeting of the US Advisory Committee on Immunization ...

(WJET/WFXP) — UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now ...

Oct 9 (Reuters) - GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.